Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies. Its products are being sold in India and also exported to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020. Glenmark Pharmaceuticals Limited is the promoter of the company.

For year/ period ended ( in Cr.)

• It is a leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
• Export products in Europe, Latin America, North America, Japan, and the rest of the world.
• The Company has strong Relationships with Leading Global Generic Companies.
• Proven track record of strong financial performance.
• High-quality product manufacturing with R&D infrastructure.

• To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
• To finance capital expenditure requirements.

With the strong promoter background & consistent financial performance, the company will get premium valuation in the market. Hence, investor can subscribe to the issue for the medium to long-term.